CN1116287C - 用作钾通道调节剂的二苯基杂环化合物 - Google Patents

用作钾通道调节剂的二苯基杂环化合物 Download PDF

Info

Publication number
CN1116287C
CN1116287C CN97196891A CN97196891A CN1116287C CN 1116287 C CN1116287 C CN 1116287C CN 97196891 A CN97196891 A CN 97196891A CN 97196891 A CN97196891 A CN 97196891A CN 1116287 C CN1116287 C CN 1116287C
Authority
CN
China
Prior art keywords
phenyl
chloro
trifluoromethyl
hydroxyphenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97196891A
Other languages
English (en)
Chinese (zh)
Other versions
CN1226803A (zh
Inventor
J·L·罗密尼
S·W·马丁
P·赫瓦瓦萨姆
N·A·密威尔
V·K·格里布科夫
J·E·小斯塔雷特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1226803A publication Critical patent/CN1226803A/zh
Application granted granted Critical
Publication of CN1116287C publication Critical patent/CN1116287C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN97196891A 1996-07-31 1997-07-30 用作钾通道调节剂的二苯基杂环化合物 Expired - Fee Related CN1116287C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2298396P 1996-07-31 1996-07-31
US60/022,983 1996-07-31

Publications (2)

Publication Number Publication Date
CN1226803A CN1226803A (zh) 1999-08-25
CN1116287C true CN1116287C (zh) 2003-07-30

Family

ID=21812455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97196891A Expired - Fee Related CN1116287C (zh) 1996-07-31 1997-07-30 用作钾通道调节剂的二苯基杂环化合物

Country Status (18)

Country Link
US (3) US5869509A (enExample)
EP (1) EP0915856A4 (enExample)
JP (1) JP2000516925A (enExample)
KR (1) KR20000029735A (enExample)
CN (1) CN1116287C (enExample)
AR (1) AR008110A1 (enExample)
AU (1) AU711736B2 (enExample)
BR (1) BR9710793A (enExample)
CZ (1) CZ32199A3 (enExample)
HU (1) HUP0000063A3 (enExample)
IL (1) IL128308A (enExample)
NO (1) NO990428L (enExample)
NZ (1) NZ334403A (enExample)
PL (1) PL331385A1 (enExample)
RU (1) RU2175319C2 (enExample)
TW (1) TW467902B (enExample)
WO (1) WO1998004135A1 (enExample)
ZA (1) ZA976554B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
ID26909A (id) 1998-01-29 2001-02-15 Bristol Myers Squibb Co Turunan-turunan 1,3,4-oksadiazolon
JP2002501926A (ja) * 1998-01-29 2002-01-22 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１、３、４−オキサジアゾロンのホスフェート誘導体
EP1056730A4 (en) * 1998-01-29 2003-01-02 Bristol Myers Squibb Co Diaryl-1,3,4-oxadiazolone benzoate
JP2003525199A (ja) * 1998-01-29 2003-08-26 ブリストル−マイヤーズ スクイブ カンパニー ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
DE19816882A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6297241B1 (en) 1999-01-29 2001-10-02 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
WO2000044745A1 (en) * 1999-01-29 2000-08-03 Bristol-Myers Squibb Company Carbamate derivatives of diaryl 1,3,4-oxadiazolone
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
GB2361003A (en) * 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
HUP0303559A3 (en) * 2000-10-13 2006-02-28 Bristol Myers Squibb Co Selective maxi-k-potassium channel openers functional under conditions of high intracellular calcium concentration and uses thereof
DE10056344A1 (de) * 2000-11-14 2002-05-16 Degussa n-Propylethoxysiloxane, Verfahren zu deren Herstellung und deren Verwendung
DE10058461A1 (de) * 2000-11-24 2002-09-19 Bayer Ag Substituierte Cyclohexanderivate und ihre Verwendung
US6855829B2 (en) 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
ES2291455T3 (es) * 2001-03-12 2008-03-01 Avanir Pharmaceuticals Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular.
WO2002083111A2 (en) * 2001-04-16 2002-10-24 Tanabe Seiyaku Co., Ltd. Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence
US7022480B1 (en) 2001-10-11 2006-04-04 The Regents Of The University Of California Exons of the hSKCa3/KCNN3 gene
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US6613786B2 (en) 2001-11-02 2003-09-02 Bristol-Myers Squibb Company Thiophenyl triazol-3-one derivatives as smooth muscle relaxants
US7846671B2 (en) * 2002-01-28 2010-12-07 Bristol-Myers Squibb Company Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
TWI271402B (en) * 2002-10-15 2007-01-21 Tanabe Seiyaku Co Large conductance calcium-activated K channel opener
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
RU2005134670A (ru) * 2003-04-10 2006-06-10 Аванир Фармасьютикалс (Us) Производные имидазола для лечения аллергических и гиперпролиферативных нарушений
GB0315111D0 (en) * 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
CA2533990A1 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
AU2005230867A1 (en) * 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
CA2561718A1 (en) * 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
EP1773790B1 (en) * 2004-07-27 2012-08-15 F.Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
CA2583177A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
DK1817295T3 (da) 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Triazolforbindelser, der modulerer HSP90-aktivitet
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
US8629285B2 (en) * 2005-08-18 2014-01-14 Synta Pharmaceuticals Corp. Imidazole compounds that modulate HSP90 activity
CA2618628C (en) * 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
AU2007267852A1 (en) * 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Compounds that modulate Hsp90 activity and methods for identifying same
TW200804314A (en) 2006-05-25 2008-01-16 Synta Pharmaceuticals Corp Triazole compounds that modulate Hsp90 activity
AU2007267847B2 (en) * 2006-05-25 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity
JP5410965B2 (ja) * 2006-05-25 2014-02-05 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
EP2121640A1 (en) * 2007-01-18 2009-11-25 NeuroSearch AS Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
BRPI0809617A2 (pt) 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
WO2008135447A1 (en) * 2007-05-03 2008-11-13 Neurosearch A/S Acetamide derivatives as potassium channel modulators
JP5277256B2 (ja) 2008-04-09 2013-08-28 田辺三菱製薬株式会社 ｍａｘｉ−Ｋチャネル開口薬としてのピリミジン、ピリジン及びトリアジン誘導体
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
PE20091953A1 (es) * 2008-05-08 2010-01-09 Du Pont Azoles sustituidos como fungicidas
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
WO2013067165A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
EP2822931B1 (en) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
DK2935228T3 (en) 2012-12-20 2017-10-30 Inception 2 Inc TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF
JP2016529311A (ja) 2013-09-06 2016-09-23 インセプション ２、 インコーポレイテッド トリアゾロン化合物類及びそれらの使用
US10681909B2 (en) 2014-08-29 2020-06-16 Fmc Corporation Herbicidal triazoles
CN104710379B (zh) * 2015-03-09 2017-01-18 华南理工大学 一种bms‑191011的合成方法
US12194026B2 (en) * 2018-10-26 2025-01-14 University Of South Florida Drug for treating tinnitus
JP7697954B2 (ja) * 2019-10-07 2025-06-24 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物
WO2021071802A1 (en) * 2019-10-07 2021-04-15 D. E. Shaw Research, Llc Aryl heterocyclic compounds as kv1.3 potassium shaker channel blockers
CN115504940A (zh) * 2021-06-23 2022-12-23 中国科学院上海药物研究所 一种酰胺类化合物、其制备方法和制药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971803A (en) * 1973-05-21 1976-07-27 Ciba-Geigy Corporation 3-Hydroxybenzyl-oxadiazolone and -thiadiazolone derivatives
US5116858A (en) * 1989-04-26 1992-05-26 Mitsubishi Kasei Corporation 4-imidazoline derivatives
WO1993008800A1 (en) * 1991-11-07 1993-05-13 New York University Potassium channel activating compounds and methods of use thereof
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545646B1 (de) * 1965-12-15 1969-09-18 Boehringer Sohn Ingelheim 1,3-Dimethyl-4-(2',4'-dichlorphenyl)-1,2,4-triazolon-(5) und Verfahren zu dessen Herstellung
DE2940709A1 (de) * 1979-10-08 1981-04-16 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von in 1-stellung substituierten imidazolen
US4966909A (en) * 1989-12-20 1990-10-30 Merrell Dow Pharmaceuticals 4-benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-ones and their use as anticonvulsants
DE4015535A1 (de) * 1990-05-15 1991-11-21 Basf Ag Verfahren zur herstellung von n-substituierten imidazolen
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
IT1251488B (it) * 1991-09-17 1995-05-15 Mini Ricerca Scient Tecnolog Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
DK28893D0 (da) * 1993-03-15 1993-03-15 Neurosearch As Benzimidazole derivater, deres fremstilling og anvendelse
US5612363A (en) * 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
IL124364A (en) * 1995-11-09 2001-08-08 Synthelabo 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol -2(3h)- one derivatives, their preparation and pharmaceutical compositions comprising them
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3971803A (en) * 1973-05-21 1976-07-27 Ciba-Geigy Corporation 3-Hydroxybenzyl-oxadiazolone and -thiadiazolone derivatives
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US5116858A (en) * 1989-04-26 1992-05-26 Mitsubishi Kasei Corporation 4-imidazoline derivatives
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
WO1993008800A1 (en) * 1991-11-07 1993-05-13 New York University Potassium channel activating compounds and methods of use thereof

Also Published As

Publication number Publication date
NO990428D0 (no) 1999-01-29
AU711736B2 (en) 1999-10-21
BR9710793A (pt) 1999-08-17
US6271249B1 (en) 2001-08-07
HUP0000063A3 (en) 2001-04-28
EP0915856A1 (en) 1999-05-19
NZ334403A (en) 2000-09-29
US6077861A (en) 2000-06-20
TW467902B (en) 2001-12-11
ZA976554B (en) 1999-01-25
KR20000029735A (ko) 2000-05-25
WO1998004135A1 (en) 1998-02-05
HUP0000063A2 (hu) 2001-01-29
NO990428L (no) 1999-01-29
EP0915856A4 (en) 2006-04-12
IL128308A (en) 2004-09-27
IL128308A0 (en) 1999-11-30
PL331385A1 (en) 1999-07-05
CN1226803A (zh) 1999-08-25
JP2000516925A (ja) 2000-12-19
US5869509A (en) 1999-02-09
AU4067997A (en) 1998-02-20
CZ32199A3 (cs) 1999-06-16
AR008110A1 (es) 1999-12-09
RU2175319C2 (ru) 2001-10-27

Similar Documents

Publication Publication Date Title
CN1116287C (zh) 用作钾通道调节剂的二苯基杂环化合物
JP3290657B2 (ja) アンギオテンシンｉｉ拮抗剤として活性な酸性アラルキルトリアゾール誘導体
US8026262B2 (en) Chemical compounds
US20090170907A1 (en) Chemical Compounds
EP0371438B1 (en) 3,5-Di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxiphenyl- 1,2,4-thiadiazoles, -oxadiazoles as antiinflammatory agents
RU2382770C2 (ru) Производные тетрагидрокарбазолов, способ их получения и фармацевтические композиции, содержащие их
JP2007533743A (ja) アルツハイマー病治療のためのβ−セクレターゼ阻害薬として有用な１，３，５−置換フェニル誘導体化合物
SK12752002A3 (sk) Substituované 3-fenyl-5-alkoxy-1,3,4-oxdiazol-2-óny, spôsob ich prípravy a ich použitie ako liečivo na inhibovanie hormónsenzitívnej lipázy
CN1150175C (zh) 1,3,4－噁二唑酮衍生物
US5155122A (en) 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
US5939405A (en) Phosphate derivatives of diaryl 1,3,4-oxadiazolone
AU736712B2 (en) Benzoate derivatives of diaryl 1,3,4-oxadiazolone
HK1022247A (en) Diphenyl heterocycles as potassium channel modulators
KR20010101869A (ko) 디아릴 1,3,4-옥사디아졸론의 카바메이트 유도체
JP2003525199A (ja) ジアリール１，３，４−オキサジアゾロンアミノ酸誘導体
MXPA99000964A (en) Diphenyl heterocycles as potassium channel modulators

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1022247

Country of ref document: HK